Article
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
The Lancet. Oncology - 1 Jul 2016
Planchard David, Besse Benjamin, Groen Harry J M, Souquet Pierre-Jean, Quoix Elisabeth, Baik Christina S, Barlesi Fabrice, Kim Tae Min, Mazieres Julien, Novello Silvia, Rigas James R, Upalawanna Allison, D'Amelio Anthony M, Zhang Pingkuan, Mookerjee Bijoyesh, Johnson Bruce E
Abstract excerpt
BACKGROUND: BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown antitumour activity in patients with BRAF(V600E)-mutant NSCLC. Dual MAPK pathway inhibition with BRAF and MEK inhibitors in BRAF(V600E)-mutant NSCLC might improve efficacy over BRAF inhibitor monotherapy based on observations in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.